Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis
Elizabeth Appiah‐Kusi, Natalia Petros, Rebecca Wilson, et al.
Psychopharmacology (2020) Vol. 237, Iss. 4, pp. 1121-1130
Open Access | Times Cited: 75

Showing 1-25 of 75 citing articles:

Cannabidiol: pharmacology and therapeutic targets
Stevie C. Britch, Shanna Babalonis, Sharon Walsh
Psychopharmacology (2020) Vol. 238, Iss. 1, pp. 9-28
Open Access | Times Cited: 220
Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications
Ainhoa Bilbao, Rainer Spanagel
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 107
Preventive interventions for individuals at ultra high risk for psychosis: An updated and extended meta-analysis
Cristina Mei, Mark van der Gaag, Barnaby Nelson, et al.
Clinical Psychology Review (2021) Vol. 86, pp. 102005-102005
Open Access | Times Cited: 98
Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis
Deepak Cyril D’Souza, Marta Di Forti, Suhas Ganesh, et al.
The World Journal of Biological Psychiatry (2022) Vol. 23, Iss. 10, pp. 719-742
Closed Access | Times Cited: 63
Adverse Effects of Oral Cannabidiol: An Updated Systematic Review of Randomized Controlled Trials (2020–2022)
José Diogo R. Souza, Júlia Cozar Pacheco, Giordano Novak Rossi, et al.
Pharmaceutics (2022) Vol. 14, Iss. 12, pp. 2598-2598
Open Access | Times Cited: 38
The therapeutic potential of purified cannabidiol
Saoirse E. O′Sullivan, Sanne Jensen, Gitte Nykjaer Nikolajsen, et al.
Journal of Cannabis Research (2023) Vol. 5, Iss. 1
Open Access | Times Cited: 29
Cannabidiol: Bridge between Antioxidant Effect, Cellular Protection, and Cognitive and Physical Performance
George Jîtcă, Bianca Eugenia Ősz, Camil-Eugen Vari, et al.
Antioxidants (2023) Vol. 12, Iss. 2, pp. 485-485
Open Access | Times Cited: 24
Cannabidiol and its Potential Evidence-Based Psychiatric Benefits – A Critical Review
Inga Dammann, Cathrin Rohleder, F. Markus Leweke
Pharmacopsychiatry (2024) Vol. 57, Iss. 03, pp. 115-132
Closed Access | Times Cited: 13
Salivary cortisol measures across the clinical stages of psychosis: An individual participant data (IPD) meta-analysis
Susanne Häußler, Uzma Zahid, Fern Day, et al.
Psychoneuroendocrinology (2025), pp. 107283-107283
Closed Access | Times Cited: 1
Therapeutic potential of cannabidiol polypharmacology in neuropsychiatric disorders
Olivier J. Manzoni, Antonia Manduca, Viviana Trezza
Trends in Pharmacological Sciences (2025)
Open Access | Times Cited: 1
Corticolimbic circuitry as a druggable target in schizophrenia spectrum disorders: a narrative review
Abigail Gee, Paola Dazzan, Anthony A. Grace, et al.
Translational Psychiatry (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Is the Adolescent Brain at Greater Vulnerability to the Effects of Cannabis? A Narrative Review of the Evidence
Grace Blest‐Hopley, Marco Colizzi, Vincent Giampietro, et al.
Frontiers in Psychiatry (2020) Vol. 11
Open Access | Times Cited: 66
Opportunities, Challenges and Pitfalls of Using Cannabidiol as an Adjuvant Drug in COVID-19
Barbara Malinowska, Marta Baranowska‐Kuczko, Aleksandra Kicman, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 4, pp. 1986-1986
Open Access | Times Cited: 46
Tetrahydrocannabinol and cannabidiol medicines for chronic pain and mental health conditions
Jeremy D. Henson, Luis Vitetta, Sean Hall
Inflammopharmacology (2022) Vol. 30, Iss. 4, pp. 1167-1178
Open Access | Times Cited: 30
Cannabinoids and the endocannabinoid system in fibromyalgia: A review of preclinical and clinical research
Stephanie Bourke, Anne Katrin Schlag, Saoirse E. O’Sullivan, et al.
Pharmacology & Therapeutics (2022) Vol. 240, pp. 108216-108216
Open Access | Times Cited: 28
Unraveling the Intoxicating and Therapeutic Effects of Cannabis Ingredients on Psychosis and Cognition
Marco Colizzi, Mirella Ruggeri, Sagnik Bhattacharyya
Frontiers in Psychology (2020) Vol. 11
Open Access | Times Cited: 49
The Impact of Feeding Cannabidiol (CBD) Containing Treats on Canine Response to a Noise-Induced Fear Response Test
Elizabeth M. Morris, Susanna E. Kitts-Morgan, Dawn Spangler, et al.
Frontiers in Veterinary Science (2020) Vol. 7
Open Access | Times Cited: 40
Safety and tolerability of natural and synthetic cannabinoids in adults aged over 50 years: A systematic review and meta-analysis
Latha Velayudhan, Katie McGoohan, Sagnik Bhattacharyya
PLoS Medicine (2021) Vol. 18, Iss. 3, pp. e1003524-e1003524
Open Access | Times Cited: 38
Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled, Randomized Clinical Trial
F. Markus Leweke, Cathrin Rohleder, C.W. Gerth, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 36
Hippocampal circuit dysfunction in psychosis
Samuel Knight, Robert A. McCutcheon, Daniella Dwir, et al.
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 27
Do biological alterations precede the onset of psychosis? A systematic review and meta-analysis of immune, cardiometabolic, prolactin and HPA axis alterations in clinical high-risk for psychosis
Clàudia Aymerich, Borja Pedruzo, Gonzalo Salazar de Pablo, et al.
Brain Behavior and Immunity (2025)
Open Access
Effects of Hemp Extract on Markers of Wellness, Stress Resilience, Recovery and Clinical Biomarkers of Safety in Overweight, But Otherwise Healthy Subjects
Hector L. Lopez, Kyle Cesareo, Betsy Raub, et al.
Journal of Dietary Supplements (2020) Vol. 17, Iss. 5, pp. 561-586
Closed Access | Times Cited: 38
Cannabidiol (CBD) as a novel treatment in the early phases of psychosis
Edward Chesney, Dominic Oliver, Philip McGuire
Psychopharmacology (2021) Vol. 239, Iss. 5, pp. 1179-1190
Open Access | Times Cited: 32
A meta-analysis of blood and salivary cortisol levels in first-episode psychosis and high-risk individuals
Błażej Misiak, Marita Pruessner, Jerzy Samochowiec, et al.
Frontiers in Neuroendocrinology (2021) Vol. 62, pp. 100930-100930
Open Access | Times Cited: 31
Cannabidiol-based natural health products for companion animals: Recent advances in the management of anxiety, pain, and inflammation
Cindy H. J. Yu, H.P. Vasantha Rupasinghe
Research in Veterinary Science (2021) Vol. 140, pp. 38-46
Closed Access | Times Cited: 27
Page 1 - Next Page

Scroll to top